title: Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.
abstract: The ability to predict complete pathologic response or sensitivity to radiation before treatment would have a significant impact on the selection of patients for preoperative radiotherapy or chemo-radiation therapy schedules. The aim of this study was to determine the value of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), p53, Bcl-2 and apoptosis protease-activating factor-1 (APAF-1) as predictors of complete pathologic tumour regression in patients undergoing preoperative radiotherapy for advanced rectal cancer. Pretreatment tumour biopsies from predominantly cT3 patients undergoing a preoperative high-dose-rate brachytherapy protocol were immunostained for EGFR, VEGF, p53, Bcl-2 and APAF-1. Immunoreactivity was evaluated by three pathologists. Cut-off scores for tumour marker positivity were obtained by receiver-operating characteristic (ROC) curve analysis. The association of marker expression with complete pathologic response was analysed in univariate and multivariable analysis. Multi-marker phenotypes of the independent protein markers were evaluated. In multivariable analysis, loss of VEGF (P-value=0.009; odds ratio (OR) (95% CI)=0.24 (0.08-0.69)) and positive EGFR (P-value=0.01; OR (95% CI)=3.82 (1.37-10.6)) both demonstrated independent predictive value for complete pathologic response. The odds of complete response were 12.8 for the multi-marker combination of VEGF-negative and EGFR-positive tumours. Of the 34 EGFR-negative- and VEGF-positive cases, 32 (94.1%) had no complete pathologic response. The combined analysis of VEGF and EGFR is predictive of complete pathologic response in patients undergoing preoperative radiotherapy. In addition, the findings of this study have identified a subgroup of simultaneous EGFR-negative and VEGF-positive patients who are highly resistant to radiotherapy and should perhaps be considered candidates for innovative neoadjuvant combined modalities.
authors.affiliation: Institute of Pathology, University Hospital of Basel, Schönbeinstrasse 40, Basel 4031, Switzerland. izlobec@uhbs.ch
authors.forename: I
authors.initials: I
authors.lastname: Zlobec
authors.forename: T
authors.initials: T
authors.lastname: Vuong
authors.forename: C C
authors.initials: CC
authors.lastname: Compton
authors.forename: A
authors.initials: A
authors.lastname: Lugli
authors.forename: R P
authors.initials: RP
authors.lastname: Michel
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: J R
authors.initials: JR
authors.lastname: Jass
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D000465:Algorithms; D014408:Biomarkers, Tumor / Q000032:analysis; D001918:Brachytherapy; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011300:Preoperative Care; D011379:Prognosis; D012372:ROC Curve; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D012074:Remission Induction; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors